Liz Lewis

Chief Counsel, Specialty BUs/R&D and the Head of Patient Advocacy at Takeda Oncology

About Liz

Liz Lewis currently is Chief Counsel and Head of Patient Advocacy at Takeda Oncology. Ms. Lewis is responsible for setting Takeda Oncology’s global legal strategies and priorities.  In addition she manages the day to day legal activities of the global Takeda Oncology business unit.   Ms. Lewis also heads Takeda Oncology’s patient advocacy team.   This team partners closely with oncology patient advocates and patient focused organizations throughout the world to support access to cancer therapies. Ms. Lewis is a strong advocate for patients, providing strategic insight into our patient assistance programs.

Ms. Lewis helped to create the legacy Millennium legal function and has since expanded that function to encompass the entirety of the Takeda global oncology business unit. Ms. Lewis’s pharmaceutical legal experience is broad with expertise in research and product development, product commercialization, launch, and compliance.  She played an integral role in the company’s two oncology product launches, VELCADE and NINLARO.  

Ms. Lewis’ career has spanned more than 25 years focused within the healthcare industry.   Prior joining Millennium, Ms. Lewis was a partner in the Washington DC-based law firm, Epstein, Becker and Green, where she represented healthcare and life science companies and co-chaired the firm’s pharmaceutical practice group. She has spoken, conducted seminars and published numerous articles on the subjects of commercial practices and strategies in the pharmaceutical industry, healthcare corporate compliance, healthcare fraud, federal program reimbursement and other health-related topics.  

Ms. Lewis is a graduate of the Washington College of Law at American University, where she served as an editor for the Administrative Law Journal. She earned her Bachelor of Arts in Political Science from Hamilton College, where she graduated with honors. Ms. Lewis is also a graduate of the Women's Unlimited FEW program, an active participant in industry trade organizations including PhRMA and BIO. Liz was named by the Boston Business Journal as one of the top “20 Women to Watch” in 2014.  

See all Board Members